Default Category
-
Cap and Trade in Ontario: Lafarge
Adam Fremeth; Patrick ShulistCase IVEY-9B18M134-EStrategySupplement for product 9B18M132.Starting at €8.20
-
Cap and Trade in Ontario: General Motors Company
Adam Fremeth; Patrick ShulistCase IVEY-9B18M135-EStrategySupplement for product 9B18M132.Starting at €8.20
-
Lehman Brothers
Nicholas, Tom; Chen, DavidCase HBS-810106-EEntrepreneurshipIn 2008, the U.S. financial system was in a state of crisis and Lehman Brothers went from a major Wall Street investment bank to an insolvent institution. It was a swift end for a firm that had its beginnings over 150 years prior. What would be the firm's legacy? And how, if at all, had its activities changed the course of American history?Starting at €8.20
-
Canadian Telecommunications: Industry Regulation and Policy
Adam Fremeth; Ken MarkCase IVEY-9B11M005-EStrategyThis case study is based on a high-profile issue facing the Canadian federal government that began in 2008 and was still ongoing as of December 2010. Industry Canada, working from a set of policy objectives crafted over a period of three years, had decided that in the auction sale of wireless spectrum licenses in 2008, it would set aside 40 per cent of the licenses for new entrants. This decision had come about because research indicated that Can...Starting at €8.20
-
The Canadian Television Industry Confronts Subscription Video on Demand
Adam Fremeth; Rod E. White; Kartik RaoCase IVEY-9B16M072-EStrategyIn late 2015, developments in the Canadian television industry led the incumbent players to reconsider their traditional distribution strategies. The conflux of changes to technology, regulatory reforms, and consumption patterns was complicated by the entry of new players, forcing established firms to consider revising their business models. The regulated oligopolistic industry structure that once protected the players and ensured superior perfor...Starting at €8.20
-
The American Dream in History
Nicholas, Tom; Chen, DavidCase HBS-808134-EEntrepreneurshipStarting at €8.20
-
Dot.com: Online Pet Retailing
Nicholas, Tom; Chen, DavidCase HBS-809117-EEntrepreneurshipFrom 1995 to 1999, the U.S. experienced a period of tremendous growth in its information technology (IT) sector. The IT industry, although it accounted for less than 10% of the U.S. economy's total output, contributed disproportionately to economic growth. One market that was particularly contentious was online pet supply retailing. Pet supply retailing had an estimated worth of $31 billion in 1997, and in the late 1990s, several startups and bri...Starting at €8.20
-
Al Capone
Nicholas, Tom; Chen, DavidCase HBS-809144-EEntrepreneurshipIn 1929, Chicago, IL mob boss Al Capone was at the height of his power. As head of the extensive crime organization known as "The Outfit" during most of U.S.'s Prohibition Era (1920-1933), Capone oversaw hundreds of brothels, speakeasies, and roadhouses which served as venues for gang-administered gambling, prostitution, and illegal alcohol sales. At their peak, yearly revenues from all of his enterprises combined totaled over $100 million. Capon...Starting at €8.20
-
Crosley
Nicholas, Tom; Chen, DavidCase HBS-809160-EEntrepreneurshipIn October 1941, a top secret envoy from the U.S. military was sent to Crosley Corporation in Cincinnati, Ohio to request their assistance to construct a weapon that would drastically strengthen the defenses of U.S. troops: the proximity fuze. Such a fuze would allow enemy aircraft to be shot down with a rate of accuracy well above that of previous weaponry. The task would be a challenging one, as conventional wisdom held that it took at least fo...Starting at €8.20
-
Kleiner-Perkins and Genentech: When Venture Capital Met Science
Hardymon, G. Felda; Nicholas, TomCase HBS-813102-EEntrepreneurshipGenentech is a rare success story in the biotechnology industry. Hundreds of billions of dollars of venture capital have been invested without the expected transformational effects. Established in 1976, Genentech was to develop the new science of recombinant DNA into viable therapeutic products with mass market appeal, something that most scientists agreed was at least a decade away. The founders, Herbert Boyer and Robert Swanson had limited fina...Starting at €8.20